Press Releases

Provention Bio Announces Publication in "Expert Review of Vaccines" Describing the Scientific Rationale for Developing a Vaccine for Type 1 Diabetes by Targeting Coxsackievirus B
Provention is currently developing PRV-101 as a vaccine for acute coxsackie infection and to potentially prevent the onset of T1D

OLDWICK, N.J., Jan. 3, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics aimed at intercepting and preventing immune-mediated diseases, announced today that an article supporting the development of a vaccine for Type 1 Diabetes (T1D) by targeting coxsackievirus B (CVB) infection was published in the December 2018 online issue of Expert Review of Vaccines.

(PRNewsfoto/Provention Bio, Inc.)

The publication, titled, Developing a Vaccine for Type 1 Diabetes by Targeting Coxsackievirus B , is authored by Dr. Heikki Hyöty, Faculty of Medicine and Life Science, Department of Virology at the University of Tampere in Tampere, Finland; Dr. Mikael Knip of Children's Hospital, University of Helsinki and Helsinki University Hospital in Helsinki, Finland; and Dr. Francisco Leon, Provention's co-founder and Chief Scientific Officer.

The peer-reviewed article highlights research that pinpoints enterovirus infections, specifically CVB, as a possible cause of T1D.  The article further describes ongoing progress on what could be the first human vaccine for T1D, PRV-101.  PRV-101 is a polyvalent vaccine currently being developed by Provention as a vaccine for acute coxsackie infection and to potentially prevent up to 50% of worldwide T1D cases.  PRV-101 is currently in an IND-enabling stage prior to initiation of first-in-human studies.

"Epidemiological and experimental studies indicate that approximately half of all T1D cases could be triggered by a CVB infection in early childhood," said Dr. Leon. "Based on this groundbreaking research, Provention Bio is advancing PRV-101 as the first-ever CVB vaccine designed to prevent acute infection and potentially T1D.  In addition to the potential prevention of T1D, this vaccine could have other important beneficial health effects generated by protection against acute CVB infections, which are frequent and cause significant morbidity particularly in young children. On behalf of Provention, I would like to commend Drs. Hyöty and Knip for leading this very important research."  

About Provention Bio, Inc.
Provention Bio, Inc. (Nasdaq: PRVB) is a clinical-stage biopharmaceutical company leveraging a transformational drug development strategy that is focused on the prevention or interception of immune-mediated disease.  Provention's mission is to in-license, transform and develop therapeutic candidates targeting the high morbidity, mortality and escalating costs of autoimmune and inflammatory diseases including: type 1 diabetes (T1D), Crohn's disease, ulcerative colitis, celiac disease, lupus, and certain life-threatening viral diseases. Provention's diversified portfolio includes advanced-stage product development candidates that have undergone clinical testing by other companies. For more information on Provention Bio, please visit

Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," and "intend," among others. These forward-looking statements are based on Provention's current expectations and actual results could differ materially. There are  a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to failure to obtain FDA approvals or clearances and noncompliance with FDA regulations; uncertainties of patent protection and litigation; limited research and development efforts and dependence upon third parties; substantial competition; our need for additional financing and the risks listed under "Risk factors" in our quarterly report on Form 10-Q for the quarter ended September 30, 2018 and any subsequent filings with the Securities and Exchange Commission (SEC). As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Provention does not undertake an obligation to update or revise any forward-looking statement. The information set forth herein speaks only as of the date hereof.


Media & Investor Contacts
Jason Rando / Joshua Drumm, Ph.D.
Tiberend Strategic Advisors, Inc.
T: 212 375 2665 / 212 375 2664

Cision View original content to download multimedia:

SOURCE Provention Bio, Inc.